US FDA confirms Multaq panel review
This article was originally published in Scrip
Executive Summary
The US FDAhas confirmed that its cardiovascular and renal drugs advisory committee will meet on March 18th to review Sanofi-Aventis's investigational atrial fibrillation drug Multaq (dronedarone), the follow-on candidate to amiodarone.